Tóm tắt
Objective: The aim of this study was to evaluate the outcomes of initial Paclitaxel - Carboplatin (TC) treatment in patients with advanced non - small cell lung cancer.
Methods: A total of 38 patients diagnosed with de novo NSCLC stage from IIIB to IV were underwent TC regimen from 2 to 6 cycles between February 2021 and July 2022 at Hue university of medicine and pharmacy hospital and Hue central hospital. They were assessed the response, progression - free survival, overall survival, and toxicity.
Results: The mean age was 58.4 ± 6.7. All patients had ECOG scores of 0 and 1. There was 18.4% cases with underweight. The figure for stage IV and non - squamous cell carcinoma (non - SCC) were 86.8% and 84.2%, respectively. 44.7% of patients received Pegfilgrastim. The improvement of cough, chest pain and dyspnea occurred after the first 6 weeks and maintained stable these symptoms until the 12th week. The object response rate (ORR) was 31.6%. The median progress - free survival and overall survival were 7.0 months and 14.0 months, in turn. Adverse events (AEs) at grades 3 or 4 presented 10.6% and 5.2% of patients with neutropenia and anemia. Hepatitis and renal impairment were less common.
Conclusion: In patients with previously untreated advanced non - small cell lung cancer, Paclitaxel - Carboplatin not only had efficacy and safety with an acceptable toxicity profile but also reduced the specific symptoms
Tài liệu tham khảo
Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, et al. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021;16(1):162-168.
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, et al. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer. 2021;159:144-153.
Đường Lê Thế, Vũ Hồng Thắng. Đánh giá đáp ứng của phác đồ paclitaxel - carboplatin trên nhóm bệnh nhân trên 60 tuổi. Tạp chí Ứng dụng Y học Việt Nam. 2013:186-173.
Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, advanced non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2019;393(10183):1819-1830.
Avelino CU, Cardoso RM, Aguiar SS, Silva MJ. Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel. J Bras Pneumol. 2015;41(2):133-42.
Chuyền NTH. Khảo sát chất lượng sống ở bệnh nhân ung thư phổi tiến xa được hóa trị triệu chứng. Luận văn thạc sĩ y học. 2015.
Borghaei H, Langer CJ, Paz-Ares L, Rodriguez-Abreu D, Halmos B, Garassino MC, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020;126(22):4867-4877.
Komuro M, Kaneko M, Narukawa M. Investigation of prognostic factors affecting efficacy in carboplatin- and paclitaxel-based first-line chemotherapies for advanced non-small-cell lung cancer. Tumori. 2015;101(4):424-32.
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040-2051.
Binh HTT. Nghiên cứu điều trị ung thư phổi không tế bào nhỏ giai đoạn IIIB, IV bằng hóa trị phác đồ cisplatin kết hợp với paclitaxel hoặc etoposide. Luận văn tiến sĩ y học, Trường Đại học Y Hà Nội. 2018.
Liu M, Luo N, Fang Z, Liu Q, Yi F, Wei Y, et al. The efficacy and toxicity of combination therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2021;47(2):157-167.
| Đã xuất bản | 20-05-2023 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Số 86 (2023) | |
| Phân mục | Nghiên cứu | |
| DOI | 10.38103/jcmhch.86.10 | |
| Từ khóa | Non - small cell lung cancer, advanced stage, Paclitaxel - Carboplatin |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2023 Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế